← Back to Caplin Point Laboratories Ltd. overview
Caplin Point Laboratories Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,937 cr | ₹536 cr | ₹70.25 | ₹3,209 cr | ₹2,850 cr | 18.81% | 23.72% | 0x | 27.68% |
| FY2024 | ₹1,680 cr | ₹457 cr | ₹59.9 | ₹2,698 cr | ₹2,316 cr | 19.74% | 24.39% | 0x | 27.21% |
| FY2023 | ₹1,454 cr | ₹376 cr | ₹49.18 | ₹2,191 cr | ₹1,880 cr | 20.01% | 23.97% | 0x | 25.88% |
| FY2022 | ₹1,269 cr | ₹300 cr | ₹39.26 | ₹1,736 cr | ₹1,484 cr | 20.21% | 26.01% | 0x | 23.62% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.